Neurodegenerative Disorder Therapeutics Global Market Report 2025

Description

Neurodegenerative disorder therapeutics encompass medications or gene therapies designed to therapeutically address patients with neurodegenerative disorders. These aim to directly address underlying disease pathways, focusing on neuroprotection, neurorestoration, and managing symptoms.

The primary drug categories within neurodegenerative disorder therapeutics include N-methyl-D-aspartate receptor drugs, selective serotonin reuptake inhibitors, dopamine inhibitors, and other classes. Selective serotonin reuptake inhibitors, commonly used in treating depression and certain mental illnesses, have diverse applications across conditions such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, Huntington's disease, and other related indications. These medications are typically distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.

The neurodegenerative disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides neurodegenerative disorder therapeutics market statistics, including neurodegenerative disorder therapeutics industry global market size, regional shares, competitors with a neurodegenerative disorder therapeutics market share, detailed neurodegenerative disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the neurodegenerative disorder therapeutics industry. This neurodegenerative disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurodegenerative disorder therapeutics market size has grown strongly in recent years. It will grow from $18.53 billion in 2024 to $20.04 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to aging population, rising prevalence of neurodegenerative disorders, increasing life expectancy, rising investments from pharmaceutical companies, awareness and advocacy.

The neurodegenerative disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $28.33 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to rising demand for personalized medicine, targeted therapy, increasing availability of clinical trials, rising healthcare expenditure. Major trends in the forecast period include disease-modifying therapies, non-pharmacological interventions, telemedicine and remote monitoring, technological innovations, precision therapeutics, digital health solutions, biomarker-driven trials.

The expanding occurrence of neurodegenerative disorders globally drives the growth of the market for neurodegenerative disorder therapeutics. The rise in neurodegenerative conditions is closely linked to the increasing elderly population. As per World Population Prospects, the elderly, aged 60 and above, will reach 2.1 billion by 2050, with the number of individuals over 80 years old tripling to 425 million. Reports from the Alzheimer's Association reveal that currently, around 5.8 million Americans suffer from Alzheimer's disease, projected to surge to approximately 14 million by 2050. This heightened prevalence within aging demographics elevates the demand for therapeutics, consequently propelling the neurodegenerative disorder therapeutics market.

The rising investment in research and development (R&D) for therapeutics targeting neurodegenerative disorders is expected to drive the growth of the neurodegenerative disorder therapeutics market in the future. Governments and organizations are initiating these investments for several compelling reasons, including the growing prevalence of these disorders, significant unmet medical needs, economic implications, and global health initiatives, among others. For example, in March 2023, the Government of Canada, a federal administration based in Canada, announced a $38.3 million investment aimed at advancing research into neurodegenerative diseases. As a result, the increasing investment in R&D for neurodegenerative disorder therapeutics is likely to continue propelling the growth of this market during the forecast period.

Manufacturers of neurodegenerative disorder therapeutics are forging strategic partnerships with governmental and non-governmental entities to advance therapeutic solutions for various neurodegenerative diseases. Collaboration among market players is intensifying to bolster research and development capabilities, aiming to innovate new and more efficacious treatments for these disorders. For instance, in July 2022, UK-based NRG Therapeutics partnered with Domainex to jointly develop novel small molecule disease-modifying medications targeting Parkinson's disease, motor neurone disease (MND), and other chronic neurodegenerative conditions.

Key players in the neurodegenerative disorder therapeutics market are leveraging innovative techniques, such as the Neurofilament Light Chain (NfL) blood test, to gain a competitive edge. This test enables medical professionals to detect and confirm signs of neurodegenerative disorders, enhancing diagnostic accuracy and treatment planning. Labcorp, a US-based company, introduced the Neurofilament Light Chain (NfL) blood test in July 2022, allowing for direct evidence of neuronal damage. Elevated NfL levels serve as indicators of neuronal damage caused by conditions like multiple sclerosis, Alzheimer's, Parkinson's disease, or brain injuries such as concussions. NfL, a neuron-specific protein, is a non-specific biomarker for various neurodegenerative conditions like Alzheimer's disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), released in response to neuronal injury and neurodegeneration.

In January 2022, VitalPath, a US-based manufacturer of catheters and catheter shafts acquired Modern Catheter Technologies for an undisclosed amount. The acquisition will increase VitalPath's capacity for growth, bringing its entire manufacturing footprint to more than 80,000 square feet, including 35,000 square feet of ISO 7 and 8 cleanroom space. Modern Catheter Technologies is a US-based manufacturer of microcatheters used in neurovascular and electrophysiology.

Major companies operating in the neurodegenerative disorder therapeutics market include Biogen Inc., Pfizer Inc., Novartis International AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd., UCB S.A., F. Hoffmann-La Roche Ltd., ACADIA Pharmaceuticals Inc., H. Lundbeck A/S, Boehringer Ingelheim International GmbH, Merck Serono S.A., Orion Corporation, Mitsubishi Tanabe Pharma America, Allergan PLC, GlaxoSmithKline PLC, AbbVie Inc., Eli Lilly and Company, Celgene Corporation, Neuro-Hitech Inc., Bayer Schering Pharma AG, Amarin Corporation PLC, AstraZeneca plc, Alector Inc., Yumanity Therapeutics Inc., Yangtze River Pharmaceutical Group Co. Ltd., Chongqing Zein Pharmaceutical Co. Ltd., Eisai Co. Ltd., Bristol Myers Squibb Company, AB Science S.A., Amylyx Pharmaceuticals Inc., Genentech Inc., GenSight Biologics S.A., AC Immune SA, Annexon Bioscience Inc., BioArctic Neuroscience AB, Cajal Neuroscience Inc., Cognito Therapeutics Inc., Grifols S.A., New Equilibrium Biosciences Inc., Prothena Corporation PLC, Tessera Therapeutics Inc., Vigil Neuroscience Inc.

North America was the largest region in the global neurodegenerative disorder therapeutics market in 2024. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the neurodegenerative disorder therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the neurodegenerative disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The neurodegenerative disorder therapeutics market includes revenues earned by entities by correction of pathogenic mechanisms, neuroprotection, neurorestoration, and symptom control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurodegenerative Disorder Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurodegenerative disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurodegenerative disorder therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurodegenerative disorder therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Indication Type: Parkinson's Disease; Alzheimer's Disease; Multiple Sclerosis; Huntington Disease; Other Indication Types
2) By Drug Type: N- methyl- D- aspartate Receptor; Selective Serotonin Reuptake Inhibitor; Dopamine Inhibitors; Other Drug Types
3) By Distribution: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
Subsegments:
1) By Parkinson's Disease: Dopamine Agonists; MAO-B Inhibitors; COMT Inhibitors; Anticholinergics
2) By Alzheimer's Disease: Cholinesterase Inhibitors; NMDA Receptor Antagonists; Anti-Amyloid Monoclonal Antibodies
3) By Multiple Sclerosis: Immunomodulators; Immunosuppressants; Corticosteroids
4) By Huntington's Disease: Tetrabenazine; Antipsychotic Medications
5) By Other Indication Types: Amyotrophic Lateral Sclerosis (ALS) Treatments; Frontotemporal Dementia Treatments; Prion Disease Treatments
Companies Mentioned: Biogen Inc.; Pfizer Inc.; Novartis International AG; Sanofi S.A.; Teva Pharmaceutical Industries Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r32939

1. Executive Summary

2. Neurodegenerative Disorder Therapeutics Market Characteristics

3. Neurodegenerative Disorder Therapeutics Market Trends And Strategies

4. Neurodegenerative Disorder Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Neurodegenerative Disorder Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Neurodegenerative Disorder Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neurodegenerative Disorder Therapeutics Market Growth Rate Analysis
5.4. Global Neurodegenerative Disorder Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neurodegenerative Disorder Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neurodegenerative Disorder Therapeutics Total Addressable Market (TAM)

6. Neurodegenerative Disorder Therapeutics Market Segmentation

6.1. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Other Indication Types
6.2. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
N-methyl-D-aspartate Receptor
Selective Serotonin Reuptake Inhibitor
Dopamine Inhibitors
Other Drug Types
6.3. Global Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
6.4. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Parkinson's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dopamine Agonists
MAO-B Inhibitors
COMT Inhibitors
Anticholinergics
6.5. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Alzheimer's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cholinesterase Inhibitors
NMDA Receptor Antagonists
Anti-Amyloid Monoclonal Antibodies
6.6. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Multiple Sclerosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunomodulators
Immunosuppressants
Corticosteroids
6.7. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Huntington's Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tetrabenazine
Antipsychotic Medications
6.8. Global Neurodegenerative Disorder Therapeutics Market, Sub-Segmentation Of Other Indication Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amyotrophic Lateral Sclerosis (ALS) Treatments
Frontotemporal Dementia Treatments
Prion Disease Treatments

7. Neurodegenerative Disorder Therapeutics Market Regional And Country Analysis

7.1. Global Neurodegenerative Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neurodegenerative Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurodegenerative Disorder Therapeutics Market

8.1. Asia-Pacific Neurodegenerative Disorder Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurodegenerative Disorder Therapeutics Market

9.1. China Neurodegenerative Disorder Therapeutics Market Overview
9.2. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurodegenerative Disorder Therapeutics Market

10.1. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurodegenerative Disorder Therapeutics Market

11.1. Japan Neurodegenerative Disorder Therapeutics Market Overview
11.2. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurodegenerative Disorder Therapeutics Market

12.1. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurodegenerative Disorder Therapeutics Market

13.1. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurodegenerative Disorder Therapeutics Market

14.1. South Korea Neurodegenerative Disorder Therapeutics Market Overview
14.2. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurodegenerative Disorder Therapeutics Market

15.1. Western Europe Neurodegenerative Disorder Therapeutics Market Overview
15.2. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurodegenerative Disorder Therapeutics Market

16.1. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurodegenerative Disorder Therapeutics Market

17.1. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurodegenerative Disorder Therapeutics Market

18.1. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurodegenerative Disorder Therapeutics Market

19.1. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurodegenerative Disorder Therapeutics Market

20.1. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurodegenerative Disorder Therapeutics Market

21.1. Eastern Europe Neurodegenerative Disorder Therapeutics Market Overview
21.2. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurodegenerative Disorder Therapeutics Market

22.1. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurodegenerative Disorder Therapeutics Market

23.1. North America Neurodegenerative Disorder Therapeutics Market Overview
23.2. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurodegenerative Disorder Therapeutics Market

24.1. USA Neurodegenerative Disorder Therapeutics Market Overview
24.2. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurodegenerative Disorder Therapeutics Market

25.1. Canada Neurodegenerative Disorder Therapeutics Market Overview
25.2. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurodegenerative Disorder Therapeutics Market

26.1. South America Neurodegenerative Disorder Therapeutics Market Overview
26.2. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurodegenerative Disorder Therapeutics Market

27.1. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurodegenerative Disorder Therapeutics Market

28.1. Middle East Neurodegenerative Disorder Therapeutics Market Overview
28.2. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurodegenerative Disorder Therapeutics Market

29.1. Africa Neurodegenerative Disorder Therapeutics Market Overview
29.2. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Indication Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neurodegenerative Disorder Therapeutics Market, Segmentation By Distribution, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurodegenerative Disorder Therapeutics Market Competitive Landscape And Company Profiles

30.1. Neurodegenerative Disorder Therapeutics Market Competitive Landscape
30.2. Neurodegenerative Disorder Therapeutics Market Company Profiles
- 30.2.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Neurodegenerative Disorder Therapeutics Market Other Major And Innovative Companies

31.1. UCB S.A.
31.2. F. Hoffmann-La Roche Ltd.
31.3. ACADIA Pharmaceuticals Inc.
31.4. H. Lundbeck A/S
31.5. Boehringer Ingelheim International GmbH
31.6. Merck Serono S.A.
31.7. Orion Corporation
31.8. Mitsubishi Tanabe Pharma America
31.9. Allergan PLC
31.10. GlaxoSmithKline PLC
31.11. AbbVie Inc.
31.12. Eli Lilly and Company
31.13. Celgene Corporation
31.14. Neuro-Hitech Inc.
31.15. Bayer Schering Pharma AG

32. Global Neurodegenerative Disorder Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurodegenerative Disorder Therapeutics Market

34. Recent Developments In The Neurodegenerative Disorder Therapeutics Market

35. Neurodegenerative Disorder Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Neurodegenerative Disorder Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Neurodegenerative Disorder Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Neurodegenerative Disorder Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer